Skip to main content
SpringerLink
Log in

Effects of thiazolidinediones on blood pressure

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Peroxisome-proliferator-activated receptor-γ (PPAR-γ) agonists (known as thiazolidinediones; TDZs) activate nuclear receptors that regulate gene expression; they were developed as insulin-sensitizing drugs to treat type 2 diabetes mellitus. Although the prototypic TZD troglitazone was withdrawn from the market due to hepatic toxicity, rosiglitazone and pioglitazone are mainstays in managing type 2 diabetes mellitus. TZDs exert their hypoglycemic effect by reducing insulin resistance, hence improving insulin sensitivity. However, TZDs also exhibit a broad range of cardiovascular actions, with the clinical consequence of reduction in blood pressure (BP), observed in animal models and human diabetic subjects. The magnitude of reduction appears to be about 4 to 5 mm Hg in systolic and 2 to 4 mm Hg in diastolic BP—sufficient to significantly reduce subsequent cardiovascular event rates. But these BP-reducing properties, which are not present with metformin or sulfonylureas, are particularly important when viewed in conjunction with hypoglycemic effects. A significant proportion of patients with type 2 diabetes mellitus and BP mildly above target range might be successfully treated for both processes with a single drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Gurnell M, Savage DB, Chatterjee VK, O’Rahilly S: The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab 2003, 88:2412–2421.

    Article  PubMed  CAS  Google Scholar 

  2. Sarafidis PA, Nilsson PM: The effects of thiazolidinediones on blood pressure levels: a systematic review. Blood Pressure 2006, 15:135–150.

    Article  PubMed  CAS  Google Scholar 

  3. Sarafidis PA, Lasaridis AN: Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect. Am J Hypertens 2006, 19:646–653.

    Article  PubMed  CAS  Google Scholar 

  4. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004, 351:1106–1118.

    Article  PubMed  Google Scholar 

  5. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ: Nuclear receptors and lipid physiology: opening the X-files. Science 2001, 294:1866–1870.

    Article  PubMed  CAS  Google Scholar 

  6. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 2002, 53:409–435.

    Article  PubMed  CAS  Google Scholar 

  7. Berger JP, Petro AE, Macnaul KL, et al.: Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol 2003, 17:662–676.

    Article  PubMed  CAS  Google Scholar 

  8. Willson TM, Lambert MH, Kliewer SA: Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001, 70:341–367.

    Article  PubMed  CAS  Google Scholar 

  9. Dubois M, Pattou F, Kerr-Conte J, et al.: Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 2000, 43:1165–1169.

    Article  PubMed  CAS  Google Scholar 

  10. Lebovitz HE, Banerji MA: Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001, 56:265–294.

    Article  PubMed  CAS  Google Scholar 

  11. Haffner SM: Epidemiology of hypertension and insulin resistance syndrome. J Hypertens Suppl 1997, 15:S25–30.

    PubMed  CAS  Google Scholar 

  12. Natali A, Quinones Galvan A, Santoro D, et al.: Relationship between insulin release, antinatriureis and hypokalaemia after glucose ingestion in normal and hypertensive man. Clin Sci (Lond) 1993, 85:317–335.

    Google Scholar 

  13. Laakso M, Edelman SV, Brechtel G, Baron AD: Impaired insulin-mediated skeletal muscle blood flow inpatients with NIDDM. Diabetes 1992, 41:1076–1083.

    Article  PubMed  CAS  Google Scholar 

  14. Barbagallo M, Gupta RK, Bardicef O, et al.: Mieredionic effects of insulin in hypertension role of basalion levels in determining cellular responsiveness. J Clin Endocrinol Metab 1997, 82:1761–1765.

    Article  PubMed  CAS  Google Scholar 

  15. Trovati M, Anfossi G: Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function. J Diabetes Complications 2002, 16:35–43.

    Article  PubMed  Google Scholar 

  16. Picard F, Auwerx J: PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 2002, 22:167–197.

    Article  PubMed  CAS  Google Scholar 

  17. Miyazaki Y, Mahankali A, Matsuda M, et al.: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Exdocrinol Metab 2002, 87:2784–2791.

    Article  CAS  Google Scholar 

  18. Okuno A, Tamemoto H, Tobe K, et al.: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998, 101:1354–1361.

    Article  PubMed  CAS  Google Scholar 

  19. Knock A, Mishra SK, Aaronson PI: Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes. Eur J Pharmacol 1999, 368:103–109.

    Article  PubMed  CAS  Google Scholar 

  20. Kawasaki J, Hirano K, Nishimura J, et al.: Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery. Circulation 1998, 98:2446–2452.

    PubMed  CAS  Google Scholar 

  21. Fujioka Y, Masai M, Tsuboi S, et al.: Troglitazone reduces activity of the Na+/H+ exchanger in fructose-fed borderline hypertensive rats. Hypertens Res 2003, 26:111–116.

    Article  PubMed  CAS  Google Scholar 

  22. Buchanan TA, Meehan WP, Jeng Y, et al.: Bloodpressure lowering by pioglitazone: evidence for a directvascular effect. J Clin Invest 1995, 96:354–360.

    PubMed  CAS  Google Scholar 

  23. de Dios ST, Hannan KM, Dilley RJ, et al.: Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells. J Diabetes Complications 2001, 15:120–127.

    Article  PubMed  Google Scholar 

  24. Qayyum R, Schulman P: Cardiovascular effects of the thiazolidinediones. Diabetes Metab Res Rev 2006, 22:88–97.

    Article  PubMed  CAS  Google Scholar 

  25. Saku K, Zhang B, Ohta T, Arakawa K: Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits. Am J Hypertens 1997, 10:1027–1033.

    Article  PubMed  CAS  Google Scholar 

  26. Czoski-Murray C, Warren E, Chilcott J, et al.: Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technol Assess 2004, 8:1–91.

    Google Scholar 

  27. Bennett SM, Agrawal A, Elasha H, et al.: Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabetes Med 2004, 21:415–422.

    Article  CAS  Google Scholar 

  28. Sung BH, Izzo JL Jr, Dandona P, Wilson MF: Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 1999, 34:83–88.

    PubMed  CAS  Google Scholar 

  29. Negro R, Mangieri T, Dazzi D, et al.: Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract 2005, 70:20–25.

    Article  PubMed  CAS  Google Scholar 

  30. Negro R, Dazzi D, Hassan H, Pezzarossa A: Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinol 2004, 29:11–17.

    PubMed  CAS  Google Scholar 

  31. Ohigara T, Rakugi H, Ikegami H, et al.: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995, 8:316–320.

    Article  Google Scholar 

  32. Derosa G, Cicero AF, Gaddi AV, et al.: Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. Clin Ther 2005, 27:1383–1391.

    Article  PubMed  CAS  Google Scholar 

  33. Sarafidis PA, Lasaridis AN, Nilsson PM, et al.: The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am J Hypertens 2005, 18(2 Pt 1):227–234.

    Article  PubMed  CAS  Google Scholar 

  34. Raji A, Seely EW, Bekins SA, et al.: Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003, 26:172–178.

    Article  PubMed  CAS  Google Scholar 

  35. Yosefy C, Magen E, Kiselevich A, et al.: Rosiglitazone improves, while glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004, 44:215–222.

    Article  PubMed  CAS  Google Scholar 

  36. St John Sutton M, Rendell M, Dandona P, et al.: A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002, 25:2058–2064.

    Article  PubMed  Google Scholar 

  37. Qayyum R, Adomaityte J: A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens 2006, 8:19–28.

    Article  CAS  Google Scholar 

  38. Dormandy A, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) a randomised controlled trial. Lancet 2005, 366:1279–1289.

    Article  PubMed  CAS  Google Scholar 

  39. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-rist patients. N Engl J Med 2000, 342:145–153.

    Article  Google Scholar 

  40. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators—Gerstein HC, Yusuf S, Bosch J, et al.: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096–1105.

    Article  PubMed  CAS  Google Scholar 

  41. DREAM Trial Investigators—Bosch J, Yusuf S, Gerstein HC, et al.: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006, 355:1551–1562.

    Article  PubMed  Google Scholar 

  42. Cook NR, Cohen J, Hebert PR, et al.: Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995, 155:701–709.

    Article  PubMed  CAS  Google Scholar 

  43. Lewington S, Clarke R, Qizilbash N, et al., Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903–1913.

    Article  PubMed  Google Scholar 

  44. Giles TD, Berk BC, Black HR, et al., on behalf of the Writing Group of the American Society of Hypertension (ASH): Expanding the definition and classification of hypertension. J Clin Hypertens 2005, 7:505–512.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Cardiology, Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA, 70112, USA

    Thomas D. Giles MD

Authors
  1. Thomas D. Giles MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gary E. Sander MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas D. Giles MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giles, T.D., Sander, G.E. Effects of thiazolidinediones on blood pressure. Current Science Inc 9, 332–337 (2007). https://doi.org/10.1007/s11906-007-0060-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-007-0060-0

Keywords

Search

Navigation